Peptide safety
"Is this safe?" is the right first question. These articles look at peptide safety — what data actually exists for peptides and GLP-1 medications: what trials measured, what has only been studied in animals, how sourcing and compounding affect quality, and which red flags matter when you read claims online.
The prescription requirement exists precisely for this: a licensed provider weighs your health history before anything ships — and can say no. The same standard applies across the site: what a study measured, in whom, and for how long.
227 articles on this topic
-

Kisspeptin for Women: What the Research Shows
Kisspeptin has been given to women in a handful of small hospital trials — to mature eggs during IVF, to restart stalled hormone signalling, and once to watch the brain respond to sexual cues. Here is what those studies found, and what they did not.
-

Semaglutide and Tirzepatide Together? Usually No
Semaglutide and tirzepatide together are not a recommended combination. Both reach the same GLP-1 pathway; a switch should be planned as one treatment replacing the other, with timing and dose set by a prescriber.
-

TB-500 Half-Life: The Honest Answer Is Unknown
There is no reliable human half-life for the TB-500 fragment. The familiar one-to-two-hour estimate comes from the 44-amino-acid recombinant study molecule NL005, tested by a different route.
-

Tesamorelin Cycle: Why Doctors Talk About Duration
There is no on-and-off tesamorelin cycle in the research. The trials ran it daily for 26 weeks and then 52 — and when people stopped, the visceral fat came back.
-

GLP-1 Heart Failure Guidelines Changed in 2026
Europe's 2026 ESC guideline now says semaglutide or tirzepatide should be considered for a narrow group with symptomatic heart failure and obesity. It is an option for a cardiologist to weigh, not a direction to start either drug on your own.
-

How to Choose a Tirzepatide Provider: 7 Checks
Most of the difference between a careful service and a careless one shows up before a vial ever arrives — in who reads your history, who makes the medicine, and whether anyone answers afterwards.
-

Peptide Research 2026: What Three Reviews Found
Three review papers landed within a few weeks of each other this summer. They agree the animal work is real, the human evidence is thin, and that gap is the thing worth understanding.
-

CJC-1295 Ipamorelin for Muscle Growth: No Trial
These peptides can raise signals along the growth hormone pathway, but no human trial has shown that the pair builds muscle or increases strength. The honest case is a plausible mechanism, not a bodybuilding result.
-

Kisspeptin and Testosterone: Pattern Beats Amount
A study published on August 3, 2026 gave 15 healthy men kisspeptin-10 three different ways. Five days of it around the clock and the pituitary stopped answering; eight hours on and sixteen off, and it kept answering for twelve days.
-

MOTS-c Half-Life: What Is Actually Known
No published study has measured how long the body takes to clear a dose of MOTS-c. Here is what the rodent work, the exercise data and one unpublished Phase 1 trial actually show.
-

Mounjaro vs Zepbound: Same Drug, Two Labels
Both pens hold tirzepatide and run the same dose ladder. What differs is the use printed on the carton — and that is what your insurer reads.
-

Selank for Anxiety: What the Research Shows
Three small Russian trials, 192 patients, and no placebo arm between them. Here is what that evidence supports, what it doesn't, and where US regulators have landed.
-

Semaglutide for Children: What STEP Young Means
Semaglutide for children ages 6 to 11 has encouraging new trial results, but the news has not changed who can receive Wegovy under its current label. The evidence is promising, early, and best read with a pediatrician.
-

Sermorelin Nasal Spray: What Gets Past Your Nose
The one study that measured it found about 3 to 5 percent of a nasal dose reached the bloodstream. That number, and what happened when researchers kept spraying for six months, is most of the story.
-

What Is Tesamorelin Used For?
Tesamorelin has one narrow labeled use: reducing excess abdominal fat in adults with HIV-associated lipodystrophy. Uses beyond that label need a more careful answer.
-

503A Bulks List: What It Means
The 503A bulks list is a narrow ingredient pathway for patient-specific compounding. Here is how it differs from FDA categories, drug review and the separate 503B list.
-

Is BPC-157 FDA Approved? No—The Vote Was Advisory
BPC-157 is not FDA-approved, and no approved BPC-157 product exists anywhere. The July 2026 vote was advice on compounding, not drug approval.
-

Paradigm Peptides: A Lab Certificate Is Not Proof
The Paradigm Peptides sentencing exposed a simple weakness in buying medicine from an unlicensed website: a polished lab certificate can be fake. The safer difference is an accountable chain—a prescriber, a named pharmacy and records regulators can inspect.
-

Best Tirzepatide Compounding Pharmacy Checklist
The best choice is a pharmacy you can verify: licensed, tied to a real prescription, clear about sterile preparation, and accountable for the vial after it leaves the building.
-

How to Report Peptide Side Effects So It Counts
An NBC News investigation in August found that problems linked to peptides often go nowhere at all. Here is where a report actually lands, and in what order to make it.
Page 5 of 12 · 227 articles